Skip to main content
Premium Trial:

Request an Annual Quote

CareDx Closes $7.8M Public Offering

NEW YORK (GenomeWeb) – CareDx announced today that it has closed a previously announced $7.8 million public stock offering.

The molecular diagnostics company said it sold about 2.3 million shares of common stock at $4 per share. Piper Jaffray acted as sole manager for the offering.

When it announced plans for the offering a week ago, CareDx said it intended to use a majority of the $7.8 million in net proceeds to fund the continued development of AlloSure — its donor-derived cell-free DNA diagnostic for solid organ transplant recipients — including a clinical utility trial and future commercialization efforts. The rest of the funds will be used for working capital and general corporate purposes.

The company's shares rose nearly 1 percent to $3.65 in morning trading on the Nasdaq.

The Scan

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.

Active Lifestyle Linked to Type 2 Diabetes Prevention in People at High Genetic Risk

A study in the British Journal of Sports Medicine shows that an active lifestyle goes a long way in type 2 diabetes prevention.

Beneficial, Harmful Effects of Introgression Between Wild and Domesticated European Grapes

A paper in PNAS shows that European wild grapevines were an important resource for improving the flavor of cultivated wine grapes.

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.